<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>LABORATORY PREDICTORS OF SEVERE COVID-19: A SCIENTIFIC AND ANALYTICAL REVIEW OF RETROSPECTIVE STUDY DATA</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Umidakhon</mods:namePart><mods:namePart type="family">Alimova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>During the COVID-19 pandemic, laboratory biomarkers have become essential tools for evaluating disease severity, predicting complications, and determining the need for intensive therapy. This article presents a scientific and analytical synthesis of retrospective data from 350 hospitalized patients with PCR-confirmed SARS-CoV-2 infection.
Key laboratory indicators with high prognostic significance were identified: lymphopenia, neutrophil-to-lymphocyte ratio (N/L), C-reactive protein (CRP), lactate dehydrogenase (LDH), fibrinogen, D-dimer, and platelet parameters. The study established that combined immuno-inflammatory and coagulopathic abnormalities shape an integral pathogenetic profile of severe COVID-19. Particular attention is given to the U-shaped relationship between fibrinogen levels (&amp;lt;2.0 g/L or &amp;gt;9.0 g/L) and mortality risk, as well as the strong association of elevated D-dimer with thrombotic complications and multi-organ failure.
These findings underscore the necessity of continuous laboratory monitoring and highlight the importance of biomarker-based personalized patient management.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-12-08</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Center for Tech and Media Research</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>